Myung In Pharm Co

Myung In Pharm Co EBIT Margin

The EBIT Margin (Operating Margin) of Myung In Pharm Co (317450.KS) as of Nov 18, 2026 is 32.20 %. In the previous year, EBIT Margin (Operating Margin) was 34.43 % — a change of -6.46% (lower).

EBIT Margin

32.20 %

YoY

-6.46%

Last updated:

EBIT Margin (Operating Margin) of Myung In Pharm Co is 2025 32.20 % . EBIT Margin (Operating Margin) of Myung In Pharm Co was 2024 34.43 % . It decreases by -6.46% lower compared to the previous year.

For Myung In Pharm Co, the operating (EBIT) margin of 32.2% is down versus 34.5% a few years ago.

The Myung In Pharm Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2023
34.50 KRW
Jan 1, 2024
34.43 KRW
Jan 1, 2025
32.20 KRW
The Myung In Pharm Co EBIT Margin history
YEAREBIT MarginYoY
32.20 %-6.46%
34.43 %-0.23%
34.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myung In Pharm Co Stock analysis

What does Myung In Pharm Co do? Myung In Pharm Co., Ltd. generates revenue through the manufacture and sale of prescription drugs for neurology and psychiatry, including stroke and Parkinson’s disease treatments, schizophrenia, and depression therapies. The company primarily targets domestic and overseas markets, distributing its products under its own brand for neurological and psychiatric conditions. General pharmaceuticals such as dental, oral, digestive system treatments, and other related products form additional revenue streams within its domestic and international sales channels. The firm focuses on prescription drug segments, with key products addressing stroke, Parkinson’s disease, schizophrenia, and depression. These treatments are sold directly to healthcare providers and pharmacies in both domestic and overseas markets. The company also offers general pharmaceuticals like dental and oral treatments, alongside digestive system therapies, contributing to its diversified product portfolio across multiple therapeutic areas. Myung In Pharm’s business model relies on selling branded prescription medications for specific neurological and psychiatric conditions, alongside general pharmaceuticals. Its domestic and overseas market presence ensures consistent revenue from both regional and global healthcare sectors, with no additional details on specific customer segments or pricing strategies disclosed in the provided description. Myung In Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myung In Pharm Co stock

EBIT Margin (Operating Margin) of Myung In Pharm Co is 32.20 % in 2025.

EBIT Margin (Operating Margin) of Myung In Pharm Co changed from 34.43 % to 32.20 %, representing a -6.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Myung In Pharm Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Myung In Pharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Myung In Pharm Co

All Key Metrics — Myung In Pharm Co